Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study of Anlotinib in Advanced Soft Tissue Sarcoma

Trial Profile

Phase 2 Study of Anlotinib in Advanced Soft Tissue Sarcoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anlotinib (Primary)
  • Indications Alveolar soft part sarcoma; Clear cell sarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use
  • Sponsors Chia Tai Tianqing Pharmaceutical Group
  • Most Recent Events

    • 12 Jun 2018 Status changed from active, no longer recruiting to completed based on the results published in the Clinical Cancer Research.
    • 12 Jun 2018 Results published in the Clinical Cancer Research.
    • 10 May 2018 According to the Sino Biopharmaceutical media release, data from this trial was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top